Quoin Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
QNRX Quoin Pharmaceuticals Ltd
VTI Vanguard Total Stock Market Index Fund ETF Shares
INDP Indaptus Therapeutics Inc
RNAZ Transcode Therapeutics Inc
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
Go

Health Care : Biotechnology |
Based in Israel
Company profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$4.70
Day's Change
-0.30 (-6.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.19
Day's Low
4.70
Volume
(Heavy Day)
Volume:
10,279

10-day average volume:
7,575
10,279

Cano Health stock plunges toward record low after 3 directors resigned amid concerns over CEO Hernandez's leadership

2:31 pm ET March 31, 2023 (MarketWatch)
Print

Shares of Cano Health Inc. (CANO) tumbled 20.3% toward their first-ever sub $1 close in afternoon trading Friday, after the primary care provider said it was "disappointed" that three directors had decided to resign, that it strongly disagreed with their comments about the company and that one director, Barry Sternlicht, shared confidential board deliberations with shareholders. Late Thursday, Sternlicht issued a statement in which he criticized Chief Executive Marlow Hernandez and the board, and the mismanagement that led to the stock being "decimated" since its debut and the given the "crippling" debt burden. "I remain extremely troubled by the poor operating decisions and performance, by what I consider the opacity and obfuscation of information furnished to the Board, and by the inability to forecast the Company's financial performance over which Marlow and his management team have presided," Sternlicht said. The company's stock, which debuted on the New York Stock Exchange on June 4, 2021 after the merger with special-purpose acquisition company (SPAC) Jaws Acquisition Corp. was completed, has plummeted 94.0% since then.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

March 31, 2023 14:31 ET (18:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.